NCIt definition : An orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK)
1 and 2, with potential antineoplastic activity. Upon administration, ASTX029 specifically
binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated
protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the
inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway
is often upregulated in a variety of tumor cell types and plays a key role in the
proliferation, differentiation and survival of tumor cells.;
UNII : 14FDK6ISC9;
CAS number : 2095719-92-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2095719-92-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;